WebSify
Follow us on
Mail
Print

Novartis India Limited – OTC Business Unit, Launches Otrivin in a Nasal Spray Format

Source : BUSINESS_WIRE
Last Updated: Thu, Jan 03, 2013 09:20 hrs

Mumbai, Maharashtra, India:
-- Novartis India launches Otrivin in a Nasal Spray format in India in the OTC category.

-- Otrivin Nasal Spray, priced at Rs 44 for a 10 ml spray bottle, will be available at chemist stores. It can be bought without a prescription.

-- Otrivin will now be available as a topical nasal decongestant in a modern easy-to-use direct acting spray format, used for the relief of nasal congestion in cases of common cold, sinusitis and rhinitis.

-- The nasal spray can also be used as a dropper.



-- Otrivin acts locally inside the nose resulting in relief from blocked nose within 2 minutes and works for as long as 10 hours helping a person with a blocked nose to keep pace with his/her normal routine

Novartis India Limited – OTC Business Unit, part of Novartis’ operations in India, launched Otrivin in a Nasal Spray format. Otrivin will now be available as a topical nasal decongestant in a modern easy-to-use direct acting spray format in India. Otrivin Nasal Spray will be available over-the-counter (OTC) at chemist stores and is priced at Rs 44 for a 10 ml unit.

Otrivin has been the market leader in the Nasal Decongestant category, and has been trusted by health care professionals for several decades. It is now available as an OTC nasal decongestant in spray form that acts directly by constricting the blood vessels in the nasal tissues leading to relief from nasal congestion. Otrivin formulation comprises of Xylometazoline 0.1% and is indicated for the symptomatic relief of nasal congestion due to colds, seasonal and perennial allergic rhinitis and sinusitis. The product is positioned to be a part of the cough/cold and allergies segment, an estimated Rs 1,550 crore market in India. Of this, the nasal decongestion segment is about Rs 110 crore. Current market share of Otrivin is approximately 27% as per ORG-IMS MAT June'09 figures. With Otrivin as an OTC the market share is expected to increase by 3-5%

The OTC nasal decongestion segment comprises remedies ranging from balms to tablets, inhalers and nasal drops. In the case of Otrivin nasal spray, in order to apply the medication the consumer needs to hold his head upright and simultaneously spray the medication in a nostril and inhale. The nasal spray can also be used as a dropper.

“A common cold can slow down the pace of life. Our target group is each and every consumer who is not able to keep pace with their normal routine because of nasal congestion and is looking for fast relief. Otrivin nasal spray will help them manage their common cold symptoms more efficiently though a direct acting solution. It acts locally inside the nose within 2 minutes and works for as long as 10 hours.” said Mr Vineet Singhal, OTC BU Head India for Novartis.

About Novartis

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Contact:
Svetlana Pinto, Corporate Communications, Novartis India Limited, +91 (22) 24951074 / +91 98210 54884

blog comments powered by Disqus
most popular on facebook
talking point on sify finance